⌕
Vaxcyte · PCVX · Nasdaq
Tenet 46 · Mixed
Compare
$59.40−3.59%At closeTenet 46 · Mixed
$59.40−2.21 (−3.59%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Vaxcyte (PCVX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is PCVX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Defense WorldNov 17, 2026 · 01:44 ET
Vaxcyte (NASDAQ:PCVX) Shares Cross Below Fifty Day Moving Average Following Insider Selling

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) shares crossed below its 50 day moving average during trading on Monday after an insider sold shares in the company. The stock has a 50 day moving average of $62.25 and trad…

PCVX −3.6% todayRead at source ↗
● Defense WorldNov 9, 2026 · 04:05 ET
Candriam S.C.A. Acquires 239,206 Shares of Vaxcyte, Inc. $PCVX

Candriam S.C.A. increased its holdings in Vaxcyte, Inc. (NASDAQ: PCVX) by 115.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 447,260 sha…

PCVX −3.6% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 A…

PCVX −3.6% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 10:55 ET
Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

The mean of analysts' price targets for Vaxcyte (PCVX) points to an 87.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earning…

PCVX −3.6% todayRead at source ↗
● Defense WorldOct 18, 2026 · 02:15 ET
Vaxcyte, Inc. (NASDAQ:PCVX) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst h…

PCVX −3.6% todayRead at source ↗
● Zacks Investment ResearchOct 14, 2026 · 10:56 ET
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings…

PCVX −3.6% todayRead at source ↗
● Defense WorldOct 12, 2026 · 02:02 ET
Vaxcyte (NASDAQ: PCVX) raises $575 million with notes and stock sale

What happened Vaxcyte, Inc. (NASDAQ: PCVX) closed a financing on October 9, 2026, and sold $575 million of 1.50% convertible senior notes due 2032. The notes are senior unsecured obligations. The initial conversion rate …

PCVX −3.6% todayRead at source ↗
● Defense WorldOct 8, 2026 · 07:13 ET
Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Company Stock

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) EVP Jim Wassil sold 18,000 shares of the company's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $86.74, for a total transact…

PCVX −3.6% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 22:48 ETCOMPANY'S OWN WORDS
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares…

PCVX −3.6% todayRead at source ↗
● Seeking AlphaOct 6, 2026 · 16:04 ET
Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027

Vaxcyte remains a 'Strong Buy' after robust phase 3 OPUS-1 results for VAX-31, demonstrating non-inferiority to Prevnar 20 and Capvaxive in adults. The company offers significant upside with multiple 2027 catalysts: OPUS…

PCVX −3.6% todayRead at source ↗
● Defense WorldOct 6, 2026 · 10:20 ET
Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase Following Analyst Upgrade

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) shares saw unusually-strong trading volume on Tuesday after Needham and Company LLC raised their price target on the stock from $110.00 to $122.00. Needham and Company LLC c…

PCVX −3.6% todayRead at source ↗
● Defense WorldOct 6, 2026 · 08:02 ET
Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial

Vaxcyte (NASDAQ: PCVX) said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults. The randomized, do…

PCVX −3.6% todayRead at source ↗
● GlobeNewsWireOct 5, 2026 · 16:28 ETCOMPANY'S OWN WORDS
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its …

PCVX −3.6% todayRead at source ↗
● Seeking AlphaOct 5, 2026 · 13:40 ET
Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript

Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript…

PCVX −3.6% todayRead at source ↗
● Proactive InvestorsOct 5, 2026 · 11:17 ET
Vaxcyte shares surge on late-stage vaccine trial success

Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-sta…

PCVX −3.6% todayRead at source ↗
● Defense WorldOct 5, 2026 · 11:01 ET
Vaxcyte (NASDAQ:PCVX) Stock Sees Heavy Call Option Buying

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) saw unusually large options trading activity on Monday. Investors bought 2,615 call options on the stock. This represents an increase of approximately 17% compared to the av…

PCVX −3.6% todayRead at source ↗
● BarronsOct 5, 2026 · 10:23 ET
Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.…

PCVX −3.6% todayRead at source ↗
● Defense WorldOct 5, 2026 · 10:01 ET
Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week High – Here’s Why

Shares of Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) reached a new 52-week high on Monday. The company traded as high as $89.00 and last traded at $87.1950, with a volume of 1927060 shares trading hands. The stock ha…

PCVX −3.6% todayRead at source ↗
● BenzingaOct 5, 2026 · 08:55 ET
Vaxcyte Stock Hits New 52-Week High - Here's Why

Vaxcyte Inc. (NASDAQ:PCVX) stock is surging on Monday on positive topline results from its pivotal Phase 3 OPUS-1 trial evaluating VAX-31, an investigational 31-valent pneumococcal conjugate vaccine.…

PCVX −3.6% todayRead at source ↗
● GlobeNewsWireOct 5, 2026 · 06:00 ETCOMPANY'S OWN WORDS
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate

VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21)…

PCVX −3.6% todayRead at source ↗
● GlobeNewsWireOct 4, 2026 · 17:00 ETCOMPANY'S OWN WORDS
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate

SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8:0…

PCVX −3.6% todayRead at source ↗
● Zacks Investment ResearchSep 22, 2026 · 11:56 ET
4 Biotech Stocks With Key Clinical Readouts Expected This Fall

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.…

PCVX −3.6% todayRead at source ↗
● Defense WorldSep 15, 2026 · 03:25 ET
California State Teachers Retirement System Has $475.89 Million Stake in Vaxcyte, Inc. $PCVX

California State Teachers Retirement System boosted its position in Vaxcyte, Inc. (NASDAQ: PCVX) by 5,915.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission.…

PCVX −3.6% todayRead at source ↗
● Defense WorldSep 9, 2026 · 01:21 ET
Vaxcyte Target of Unusually High Options Trading (NASDAQ:PCVX)

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock investors acquired 3,549 put options on the company. This is an increase of approximately 52% compared to…

PCVX −3.6% todayRead at source ↗
● GlobeNewsWireSep 3, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar…

PCVX −3.6% todayRead at source ↗
● GlobeNewsWireAug 27, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Vaxcyte to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats and host one-on-…

PCVX −3.6% todayRead at source ↗

No upcoming events in the feeds.

NVDA36−0.4%
INTC4−0.5%
LAW4−8.6%
ABR3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just PCVX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.